The FDA Approves J&J, Bayer's Xarelto
The FDA Approves J&J, Bayer's Xarelto
Introduction
On Monday, Oct.14, Johnson & Johnson's (J&J) subsidiary Janssen Pharmaceutical announced that the U.S. Food and Drug Administration (FDA) approved Xarelto (rivaroxaban) for the prevention of blood clots in acutely ill patients without a high risk of bleeding during and after hospitalization.
Xarelto is an anticoagulant manufactured by Bayer and jointly marketed by Janssen Pharmaceuticals. Including the latest approval, Xarelto now has eight indications, six of which are specifically for the treatment, prevention, and reduction in the risk of recurrence of blood clotting.
Xarelto has been allegedly linked to causing uncontrollable bleeding, which leads to unexpected serious injuries and even death. Xarelto lawsuits are consolidated under the federal multidistrict litigation (MDL No.2592; In Re: Xarelto (Rivaroxaban) Products Liability Litigation) in the Eastern District of Louisiana.
Comments
Latest News
Court Approves $700M Opioid Settlement for Acute Hospitals
Categories: Opioids
A federal court has approved a $700 million class-action settlement that will compensate over 1,000 acute care hospitals for costs related to the opioid crisis.
The settlement consolidates four separate agreements involving major drug…
Philips Settles CPAP Lawsuits Over Toxic Foam for $1.1B
Categories: Philips CPAP/BiPAP/ASV Sleep Apnea Machines
Philips has been embroiled in legal battles following the recall of millions of CPAP, BiPAP, and ventilator devices due to toxic foam degradation.
The breakdown of the foam in these machines may release harmful chemicals, raising serious…
Texas Trial to Decide J&J’s $10B Talcum Powder Settlement
Categories: Talcum
A high-stakes trial in Texas will determine whether Johnson & Johnson (J&J) can resolve tens of thousands of talcum powder cancer lawsuits through a…